Imbalance between matrix metalloproteinases (MMP-9 and MMP-2) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in acute respiratory distress syndrome patients

ObjectiveMatrix metalloproteinases (MMPs) are known to be involved in degradation of extracellular matrix. We aimed to assess the role of MMPs and their natural inhibitors (TIMPs) in the genesis and the evolution of acute respiratory distress syndrome (ARDS). DesignProspective, clinical study. SettingIntensive care unit of a university hospital. PatientsTwenty-one patients were assigned to three different groups: Group 1 patients developed ARDS that rapidly resolved in <4 days; Group 2 patients developed ARDS lasting >8 days; Group 3 (control group) patients had clinical criteria for hospital-acquired pneumonia without ARDS. InterventionBronchoalveolar lavages were performed on day 0 of the onset of ARDS and on days 4, 8, and 12 for unresolving ARDS. For group 3, the bronchoalveolar lavages were performed on day 0 of the pneumonia. On these bronchoalveolar lavage fluids, we measured the amount of MMP-9 and -2 and their inhibitors TIMP-1 and -2. Measurements and Main ResultsThe amount of MMP-9 measured by enzyme-linked immunosorbent assay was significantly lower in the bronchoalveolar lavages from patients with ARDS (group 1 and group 2) compared with the control group (p < .01) throughout the study. The ratio MMP-9/TIMP-1 was also significantly smaller and was less than one in the two ARDS groups (p < .05) compared with the control group (group 3), where this ratio was greater than one. In the second bronchoalveolar lavages, this ratio was greater than one only in the ARDS group that rapidly resolved (group 1), whereas it stayed less than one when the ARDS was lasting (group 2). Concerning the quantity of MMP-2 and the ratio MMP-2/TIMP-2, there was no statistical difference between the three groups throughout the study. Using zymography, there was no significant difference in the amounts of active and latent MMP-9 between the three groups. Moreover, no significant difference in the quantity of latent and active MMP-2 in the three groups was noted. ConclusionThese results suggest that the MMP-9 level and MMP-9/TIMP-1 ratio play a role in the pathogenesis of ARDS and, namely, the imbalance between MMP-9 and TIMP-1 would participate in airway remodeling leading to either short- or long-course ARDS. The ratio MMP-9/TIMP-1 could be a predictive factor of the ARDS evolution.

[1]  T. Martin,et al.  Lung cytokines and ARDS: Roger S. Mitchell Lecture. , 1999, Chest.

[2]  K. Steinberg,et al.  The heterogeneity of BAL cells and protein in patients at risk for and with ARDS. , 1999, Chest.

[3]  A. Harf,et al.  Overexpression of alveolar macrophage gelatinase B (MMP-9) in patients with idiopathic pulmonary fibrosis: effects of steroid and immunosuppressive treatment. , 1999, American journal of respiratory cell and molecular biology.

[4]  P. Ward,et al.  Regulatory effects of endogenous protease inhibitors in acute lung inflammatory injury. , 1999, Journal of immunology.

[5]  M. Matthay,et al.  The alveolar space is the site of intense inflammatory and profibrotic reactions in the early phase of acute respiratory distress syndrome. , 1999, Critical care medicine.

[6]  J. Bousquet,et al.  Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. , 1998, American journal of respiratory and critical care medicine.

[7]  F. Stentz,et al.  Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to methylprednisolone treatment. , 1998, American journal of respiratory and critical care medicine.

[8]  I. Adamson,et al.  Collagenase and gelatinase activities in bronchoalveolar lavage fluids during bleomycin‐induced lung injury , 1998, The Journal of pathology.

[9]  M. Lamy,et al.  The American-European consensus conference on ARDS, Part 2 , 1998, Intensive Care Medicine.

[10]  T. Martin.  Cytokines and the acute respiratory distress syndrome (ARDS): A question of balance , 1997, Nature Medicine.

[11]  C. Delacourt,et al.  Gelatinases in epithelial lining fluid of patients with adult respiratory distress syndrome. , 1997, The American journal of physiology.

[12]  P. Suter,et al.  Matrix metalloproteinases and TIMP in acute respiratory distress syndrome. , 1996, American journal of respiratory and critical care medicine.

[13]  P. Suter,et al.  Proinflammatory activity in bronchoalveolar lavage fluids from patients with ARDS, a prominent role for interleukin-1. , 1996, American journal of respiratory and critical care medicine.

[14]  C. Delacourt,et al.  Imbalance between 95 kDa type IV collagenase and tissue inhibitor of metalloproteinases in sputum of patients with cystic fibrosis. , 1995, American journal of respiratory and critical care medicine.

[15]  M. Kollef,et al.  The acute respiratory distress syndrome. , 1995, The New England journal of medicine.

[16]  H. Larjava,et al.  Expression of matrix metalloproteinase-2 and -9 during early human wound healing. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[17]  A. Ishizaka,et al.  Serum concentration of 7S collagen and prognosis in patients with the adult respiratory distress syndrome. , 1994, Thorax.

[18]  K. Steinberg,et al.  Safety of bronchoalveolar lavage in patients with adult respiratory distress syndrome. , 1993, The American review of respiratory disease.

[19]  P. Bitterman.  Pathogenesis of fibrosis in acute lung injury. , 1992, The American journal of medicine.

[20]  R. Wunderink,et al.  Fibroproliferative phase of ARDS. Clinical findings and effects of corticosteroids. , 1991, Chest.

[21]  J. Woessner,et al.  Matrix metalloproteinases and their inhibitors in connective tissue remodeling , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  P. Bitterman,et al.  Failure of lung repair following acute lung injury. Regulation of the fibroproliferative response (Part 1). , 1990, Chest.

[23]  J F Murray,et al.  An expanded definition of the adult respiratory distress syndrome. , 1988, The American review of respiratory disease.

[24]  K. Iida,et al.  Higher concentrations of matrix metalloproteinases in bronchoalveolar lavage fluid of patients with adult respiratory distress syndrome. , 1997, American journal of respiratory and critical care medicine.

[25]  M. Matthay,et al.  Early detection of type III procollagen peptide in acute lung injury. Pathogenetic and prognostic significance. , 1997, American journal of respiratory and critical care medicine.

[26]  L. Mandell,et al.  Hospital-acquired pneumonia in adults: Diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies: A consensus statement , 1996 .

[27]  L. Papazian,et al.  Pulmonary fibrosis correlates with outcome in adult respiratory distress syndrome. A study in mechanically ventilated patients. , 1995, Chest.

[28]  K. Steinberg,et al.  Type III Procollagen Peptide in the Adult Respiratory Distress Syndrome: Association of Increased Peptide Levels in Bronchoalveolar Lavage Fluid with Increased Risk for Death , 1995, Annals of Internal Medicine.

[29]  H. Ishizaka,et al.  Matrix metalloproteinase; , 2022 .